The Shift to Decentralised Diagnostics

Healthcare delivery is undergoing a structural decentralisation. Driven by patient preference for convenience, advances in microfluidics, and the growth of telehealth infrastructure, diagnostic testing is rapidly shifting from centralised clinical laboratories and hospital settings directly into the patient's home.

From handheld molecular PCR-quality devices to multiplex lateral flow assays, at-home rapid diagnostic platforms are enabling earlier disease detection, improved chronic disease management, and real-time clinical monitoring. However, transitioning these technologies from the laboratory bench to global scale is not merely a technical challenge; it is a complex commercial scaling exercise. Success depends on securing commercial leadership capable of navigating fragmented reimbursement landscapes, securing B2B channel partnerships, and managing global supply chains.

The Commercial Pivot: Beyond Direct-to-Consumer

During the initial wave of digital health expansion, many diagnostics companies relied on direct-to-consumer (DTC) marketing models. However, high customer acquisition costs and the lack of structured insurance coverage proved unsustainable.

In the current market, successful diagnostics companies have pivoted toward B2B2C models. Commercial teams are targeting corporate employers, health insurance providers (payers), and pharmacy retail networks to secure large-scale, recurring revenue streams. This shift requires commercial executives who can build strategic partnerships with major telemedicine platforms, integrating diagnostic hardware with digital prescription and clinical consultation workflows.

Overcoming the Reimbursement and Regulatory Hurdles

The primary barrier to scaling a diagnostic system is not user adoption, but reimbursement. Without clear insurance coverage, at-home diagnostic platforms remain expensive out-of-pocket novelties rather than clinical standards of care.

• Payer Engagement: Commercial leaders must possess the expertise to build robust health economic and outcomes research (HEOR) data packages, proving to payers that at-home testing reduces long-term healthcare utilization costs (such as emergency room visits or unnecessary clinical consultations).

• Regulatory Navigation: Sourcing commercial executives who work in lockstep with regulatory teams is essential. Navigating the FDA’s CLIA waiver process, CE mark registrations in Europe, and the transition from prescription-only to over-the-counter (OTC) status is a critical pathway for global market entry.

• Supply Chain and Distribution: At-home diagnostic systems require physical distribution networks, shelf-life management, and temperature-controlled logistics, requiring leaders who understand both digital healthcare and physical consumer-packaged-goods (CPG) supply chains.

The Talent Mandate: Sourcing the Modern Chief Commercial Officer

As diagnostics companies scale globally, the profile of the Chief Commercial Officer (CCO) has evolved. Companies can no longer rely on sales directors from traditional laboratory service backgrounds. The modern CCO must be a cross-functional strategist capable of managing both digital health integrations and B2B payer relations.

RSA prioritises several key competencies when placing commercial leaders in the diagnostics sector:

• B2B Channel Strategy: A proven track record of securing enterprise contracts with national pharmacy chains, large employers, and insurance payers.

• HEOR and Reimbursement Fluency: The ability to translate clinical validation data into health economic models that convince payers to establish dedicated reimbursement codes.

• Global Market Expansion: Experience in scaling physical distribution networks across multiple jurisdictions, navigating localized regulatory and logistics requirements in Europe, North America, and Asia-Pacific.

By placing strategically minded, commercially fluent leaders at the helm, diagnostics companies can bridge the gap between clinical validation and global market penetration, establishing decentralised testing as the cornerstone of preventative healthcare.